Class Action Reports

ATNX Class Action: Learn About the Athenex Lawsuit

Levi & Korsinsky, LLP

March 8, 2021

Levi & Korsinsky, LLP announces that a ATNX class action lawsuit has been filed on behalf of investors who purchased Athenex, Inc. (ATNX) securities between August 7, 2019 and February 26, 2021. For more on the ATNX Lawsuit please contact us today.

 

According to the Athenex lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommend a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

TO LEARN MORE ABOUT THE ATNX CLASS ACTION LAWSUIT, CLICK HERE

 

If you suffered a loss in Athenex you have until May 3, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

 

 

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com